8000 Corporate Center Drive, Suite 200
Charlotte, NC 28226
P: (980) 859-3486 I F: (877) 202-0127
HarborPath.org

HarborPath Names Greg Weaver as Vice Chair of Board of Directors

CHARLOTTE (April 2, 2025) – HarborPath, a national nonprofit dedicated to providing life-saving specialty medications to underinsured and vulnerable populations, has named Greg Weaver as Vice Chair of its Board of Directors. Weaver, who has served as a board member since 2021, brings over 25 years of biotech financial leadership to his new role.

Weaver currently serves as Chief Financial Officer of Altimmune, a public late-stage clinical company focused on liver and metabolic disease. Throughout his career, he has successfully led multiple initial public offerings (IPOs) and raised over $1.5 billion in capital market transactions. His extensive experience in healthcare finance includes leadership roles at Cognito Therapeutics, atai Life Sciences and several other life sciences companies, where he spearheaded major capital market transactions, product launches and strategic investments.

“Greg’s deep expertise in financial strategy and biotech leadership has been invaluable to HarborPath,” said Ken Trogdon, President of HarborPath. “As we expand our impact and work to improve access to critical medications and opioid reversal tools, his guidance will be instrumental in driving our mission forward.” Vice Chair Weaver said, “I am excited to be part of the work of HarborPath and being able to focus our efforts on expanding unmet needs in healthcare.”

A United States Air Force veteran, Weaver holds a bachelor’s degree in Accounting and Finance from Trinity University and an MBA from Boston College. He has also served on the boards of multiple public and private biopharma companies, including BioIntelliSense and Rejuveron.

About HarborPath
HarborPath is a national nonprofit that provides underinsured and vulnerable patient populations in the United States with life-saving specialty medications. Through strategic partnerships, HarborPath has distributed over $129 million worth of medication at no cost to the uninsured over the last decade. Its Naloxone Right Now initiative provides communities impacted by the opioid and illicit fentanyl epidemic with access to life-saving naloxone, leveraging innovative distribution technology by FFF Enterprises to ensure timely delivery where it is needed most.